International expert consensus on the contemporary role of pelvic exenteration in recurrent or persistent cervical cancer

Study limitation reported by the research below: “Consensus statements may not fully reflect the rapidly evolving role of immunotherapy (e.g., pembrolizumab, tisotumab vedotin) in recurrent cervical cancer, which could shift the curative-intent landscape.”